Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AUBE00 is an **investigational drug** being developed by **Chugai Pharmaceutical** for the treatment of **solid tumors**. It is currently in **Phase 1 clinical trials** for patients with advanced solid malignancies. The available data indicate it is being studied as a **first-in-human therapy** to evaluate its safety, pharmacokinetics, and preliminary activity. The drug is administered orally. While the **precise modality and mechanism of action** have not been publicly disclosed, AUBE00 is mentioned among investigational antibody-drug conjugates (ADCs) in pipeline summaries, suggesting it may be an ADC or related modality. Further details on its molecular target or payload have not been released[1][2][3][4][6][7][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AUBE00.